Trovis Bio

Trovis Bio is a San Diego-based biotechnology company specializing in the development of first-in-class precision medicines for Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other chronic kidney disorders. The company leverages a proprietary platform to target the underlying molecular and metabolic drivers of cyst formation and renal decline, specifically focusing on the polycystin protein complex. Its lead programs utilize small molecule inhibitors designed to restore cellular homeostasis and provide a disease-modifying alternative to current symptomatic treatments. Trovis Bio is currently advancing its pipeline through pre-clinical development and towards IND-enabling studies. The company's mission is to address significant unmet medical needs in nephrology through genetically informed therapeutic interventions.